MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novo Nordisk A-S

Geschlossen

BrancheGesundheitswesen

67.03 -1.63

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

67

Max

68.51

Schlüsselkennzahlen

By Trading Economics

Einkommen

929M

28B

Verkäufe

14B

86B

KGV

Branchendurchschnitt

21.171

63.778

EPS

6.34

Dividendenrendite

2.33

Gewinnspanne

32.947

Angestellte

76,302

EBITDA

4.2B

40B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+49.72% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.33%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

19B

305B

Vorheriger Eröffnungskurs

68.66

Vorheriger Schlusskurs

67.03

Nachrichtenstimmung

By Acuity

73%

27%

358 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Novo Nordisk A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Feb. 2025, 15:33 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5. Feb. 2025, 11:53 UTC

Ergebnisse

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5. Feb. 2025, 08:19 UTC

Ergebnisse

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2. Apr. 2025, 11:25 UTC

Market Talk

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

31. März 2025, 12:49 UTC

Market Talk

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28. März 2025, 15:11 UTC

Market Talk

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27. März 2025, 13:45 UTC

Market Talk
Ergebnisse

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24. März 2025, 10:19 UTC

Market Talk

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24. März 2025, 09:08 UTC

Market Talk
Ergebnisse

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19. März 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11. März 2025, 15:31 UTC

Market Talk

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11. März 2025, 14:58 UTC

Market Talk

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10. Feb. 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7. Feb. 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6. Feb. 2025, 16:16 UTC

Top News
Ergebnisse

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6. Feb. 2025, 14:56 UTC

Ergebnisse

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5. Feb. 2025, 13:59 UTC

Ergebnisse

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5. Feb. 2025, 12:02 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5. Feb. 2025, 11:35 UTC

Market Talk
Ergebnisse

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5. Feb. 2025, 10:10 UTC

Heiße Aktien

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5. Feb. 2025, 09:43 UTC

Ergebnisse

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5. Feb. 2025, 08:47 UTC

Market Talk
Ergebnisse

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5. Feb. 2025, 08:38 UTC

Market Talk
Ergebnisse

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5. Feb. 2025, 08:32 UTC

Ergebnisse

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5. Feb. 2025, 08:30 UTC

Market Talk
Ergebnisse

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5. Feb. 2025, 06:46 UTC

Ergebnisse

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5. Feb. 2025, 06:45 UTC

Ergebnisse

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5. Feb. 2025, 06:43 UTC

Ergebnisse

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S Prognose

Kursziel

By TipRanks

49.72% Vorteil

12-Monats-Prognose

Durchschnitt 102.17 USD  49.72%

Hoch 124 USD

Tief 90 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

5

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

66.88 / 70.16Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

358 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.